or Try an Advanced Search...

    Technical Analysis for COGT - Cogent Biosciences, Inc.

    Grade Last Price % Change Price Change
    C 8.22 9.75% 0.73
    COGT closed up 9.75 percent on Friday, May 24, 2024, on 74 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical COGT trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Crossed Above 200 DMA Bullish 0.00%
    Bearish Engulfing Bearish 9.75%
    Fell Below 200 DMA Bearish 9.75%
    20 DMA Support Bullish 9.75%
    Slingshot Bullish Bullish Swing Setup 9.75%
    Shooting Star Candlestick Bearish 2.37%
    Stochastic Reached Overbought Strength 2.37%
    Wide Bands Range Expansion 2.37%
    Overbought Stochastic Strength 2.37%
    Older End-of-Day Signals for COGT ...

       Recent Intraday Alerts

    Alert Time
    Up 10% 4 days ago
    60 Minute Opening Range Breakout 4 days ago
    Slingshot Bullish Entry 4 days ago
    Rose Above Previous Day's High 4 days ago
    Rose Above 200 DMA 4 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    COGT Chart by TradingView
    Basic chart:

    Profile

    Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors

    Is COGT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 24 Cogent Bio spikes after updating late-stage data for lead asset
    May 23 Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
    May 23 Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
    May 13 We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
    May 7 Cogent Biosciences EPS of -$0.62 misses by $0.11
    May 7 Cogent Biosciences Reports First Quarter 2024 Financial Results
    Apr 9 Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
    Feb 28 COGT Reports Full Year 2023 Financial Results and Business Highlights
    Feb 26 Cogent downgraded at Baird on rare disease drug data
    Feb 26 Cogent Biosciences GAAP EPS of -$0.63
    See more COGT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.5
    52 Week Low 3.67
    Average Volume 1,355,531
    200-Day Moving Average 7.79
    50-Day Moving Average 6.97
    20-Day Moving Average 7.51
    10-Day Moving Average 7.68
    Average True Range 0.52
    RSI (14) 61.39
    ADX 21.42
    +DI 22.72
    -DI 16.81
    Chandelier Exit (Long, 3 ATRs) 6.73
    Chandelier Exit (Short, 3 ATRs) 7.44
    Upper Bollinger Bands 8.34
    Lower Bollinger Band 6.68
    Percent B (%b) 0.93
    BandWidth 22.10
    MACD Line 0.29
    MACD Signal Line 0.25
    MACD Histogram 0.0314
    Fundamentals Value
    Market Cap 707.94 Million
    Num Shares 86.1 Million
    EPS -2.34
    Price-to-Earnings (P/E) Ratio -3.51
    Price-to-Sales 1320.63
    Price-to-Book 3.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.62
    Resistance 3 (R3) 9.48 8.89 9.38
    Resistance 2 (R2) 8.89 8.53 8.95 9.30
    Resistance 1 (R1) 8.55 8.31 8.72 8.69 9.23
    Pivot Point 7.96 7.96 8.04 8.02 7.96
    Support 1 (S1) 7.62 7.60 7.79 7.76 7.21
    Support 2 (S2) 7.03 7.38 7.09 7.14
    Support 3 (S3) 6.69 7.03 7.06
    Support 4 (S4) 6.83